Titlebook: Anticoagulation Management; A Guidebook for Phar Anne Rose Book 2015 Springer International Publishing Switzerland 2015 Ambulatory.Care Tra

严峻考验

https://doi.org/10.1007/978-3-658-03700-0n inhibitors; however, there is emerging data to suggest the use of fondaparinux or the direct oral anticoagulants can also be used to treat HIT..This chapter will focus on the pharmacist’s role in the diagnosis, laboratory interpretation, selection of treatment options, and overall management of HIT.

注视

Ambulatory Warfarin Managementement of warfarin in the ambulatory setting is associated with improved outcomes and decreased adverse events. This chapter will focus on describing the role of the pharmacist in outpatient warfarin management and provide examples of warfarin management plans, dosing nomograms, monitoring, documentation, and patient education.

COKE

Prevention of Venous Thromboembolism..This chapter will focus on how the pharmacist can use their clinical skills to assist with identifying high VTE risk patients and selection of the most appropriate strategy to prevent VTE based on individual patient-specific risk factors.

使人烦燥

curriculum

协议

Einstellungsgespräche erfolgreich führeners. This chapter describes the role of the pharmacist in anticoagulation reversal and provides specific examples of pharmacist involvement at each step of the process: patient assessment, selection of therapy, and follow-up monitoring.

floodgate

Cardioversion

无思维能力

Unfractionated Heparin and Low Molecular Weight Heparinrriers to outpatient use if needed (self-administration techniques, financial burdens, etc). Pharmacists are in the ideal position to address all of these expectations. This chapter outlines the role of the pharmacist in the management of patients on UFH and LMWH.

慢慢流出

Anticoagulation Reversalers. This chapter describes the role of the pharmacist in anticoagulation reversal and provides specific examples of pharmacist involvement at each step of the process: patient assessment, selection of therapy, and follow-up monitoring.